Profiling the clinico-epidemiological, genomic, and immunological markers of dengue and Zika infections and co-infections in Kerala, India via longitudinal studies
- Funded by Wellcome Trust
- Total publications:0 publications
Grant number: 328498/Z/25/Z
Grant search
Key facts
Disease
Zika virus disease, Congenital infection caused by Zika virusStart & end year
20252030Known Financial Commitments (USD)
$3,129,186.09Funder
Wellcome TrustPrincipal Investigator
Dr. Amit SharmaResearch Location
IndiaLead Research Institution
International Centre for Genetic Engineering & Biotechnology, IndiaResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen genomics, mutations and adaptations
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)Infants (1 month to 1 year)
Vulnerable Population
Pregnant women
Occupations of Interest
Unspecified
Abstract
Dengue and Zika are major health threats in Kerala, with co-circulation of both viruses complicating the region's health landscape. This five-year longitudinal study, in partnership with the Kerala health system, aims to evaluate the burden, and distribution of ZIKV and DENV infections. The study will recruit >17000 probable dengue or zika patients within five days of symptom onset from healthcare facilities of all levels. Patients will be screened for infections and antibody status to determine primary or secondary infections. Active surveillance of contacts in geographical clusters will be conducted. Additionally, an antenatal cohort will be recruited and monitored for these infections. They will undergo serology testing post-delivery to assess new infections and infants will be followed for congenital anomalies in positive cases. Immune responses in asymptomatic and symptomatic individuals will be analyzed, focusing on antibody and T cell responses in mono- infections, co-infections, and sequential infections. Vectors will be examined for infection rates. A database of genomic heterogeneity will be established through next-generation sequencing to correlate with disease outcomes. The study aims to understand transmission dynamics and significant genomic and immunological readouts will help sharpen our responses to diagnostic, prognostic and management policies and potentially guiding future immunotherapeutic and vaccine developments.